Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20–30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into locoregional therapy utilization following HER2-directed syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido-Castro, Ana C., Regan, Meredith M., Niman, Samuel M., Nakhlis, Faina, Remolano, Claire, Rosenbluth, Jennifer M., Block, Caroline, Warren, Laura E., Bellon, Jennifer R., Yeh, Eren, Harrison, Beth T., Troll, Elizabeth, Lin, Nancy U., Tolaney, Sara M., Overmoyer, Beth, Lynce, Filipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238481/
https://www.ncbi.nlm.nih.gov/pubmed/37268625
http://dx.doi.org/10.1038/s41523-023-00555-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238481/
https://www.ncbi.nlm.nih.gov/pubmed/37268625
http://dx.doi.org/10.1038/s41523-023-00555-w

Ejemplares similares